XBiotech Inc.
XBIT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626878
In the last 90 days, XBiotech Inc. insiders filed 1 open-market purchase and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $4.56M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by XBiotech Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $711.3K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$711.3K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for XBiotech Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Simard Jan-Paul | Co-Chief Executive Officer | – | Oct 28, 2026 | 1 |
| Simard John | Director, 10% Owner | 4,191,690 | Oct 28, 2026 | 1 |
| Rademaker Craig Evan | Director | – | Nov 12, 2025 | 1 |
| Troy Tevi David | Director | – | Nov 12, 2025 | 1 |
| Kuendig Thomas Martin | Director | – | Nov 12, 2025 | 1 |
| Soffer David Spencer | Director | – | Nov 12, 2025 | 1 |
| McKenzie W Thorpe | Director, 10% Owner | 2,597,471 | Jun 21, 2024 | 0 |
| Waldin Jan-Paul | Director | – | Jun 21, 2024 | 0 |
| MacAdam Donald H. | Director | 10,000 | Jun 21, 2024 | 0 |
| Libby Peter | Director | 25,000 | Jun 21, 2024 | 0 |
| Shivaswamy Sushma | Chief Scientific Officer | – | Feb 17, 2023 | 0 |
| Han Queena | VP Finance & HR | – | Nov 23, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2026 (view filing)2:37 PM ET | Oct 26 | 2 days | Simard JohnDirector, 10% Owner | PPurchase | +368.5K | $1.93 | +$711.3K | +9.6%4.19M after | |
| Jan 5, 2024 (view filing) | Jan 3 | 2 days | Simard JohnChief Executive Officer | PPurchaseCommon Shares or Preferred Shares | +2.47M | $10,000,000.00 | +$24.7T | –3.84M after | DerivativePrice outlier |
| Feb 15, 2022 (view filing) | Oct 15-18, 2021 | 123 daysLate | Simard JohnChief Executive Officer | SSale | −50.0K | $13.16 | −$657.8K | −1.3%3.82M after | 2 lots |
| Oct 15, 2021 (view filing) | Oct 7-14 | 8 daysLate | Simard JohnChief Executive Officer | SSale | −89.3K | $12.67 | −$1.13M | −2.3%3.87M after | 4 lots |
| Oct 6, 2021 (view filing) | Oct 4-6 | 2 days | Simard JohnChief Executive Officer | SSale | −48.6K | $12.84 | −$624.0K | −1.2%3.96M after | 3 lots |
| Oct 1, 2021 (view filing) | Sep 28-Oct 1 | 3 daysLate | Simard JohnChief Executive Officer | SSale | −60.9K | $13.34 | −$812.2K | −1.5%4.01M after | 4 lots |
| Sep 28, 2021 (view filing) | Sep 23-27 | 5 daysLate | Simard JohnChief Executive Officer | SSale | −51.2K | $14.71 | −$753.3K | −1.2%4.07M after | 3 lots |
| Sep 22, 2021 (view filing) | Sep 20-22 | 2 days | Simard JohnChief Executive Officer | SSale | −50.0K | $15.15 | −$757.6K | −1.2%4.12M after | 3 lots |
| Jul 19, 2021 (view filing) | Jul 14 | 5 daysLate | Simard JohnChief Executive Officer | SSale | −50.0K | $18.15 | −$907.5K | −1.2%4.17M after |